Prostatype Genomics Current Valuation vs. Cash Per Share
| PROGEN Stock | SEK 11.30 0.50 4.63% |
For Prostatype Genomics profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Prostatype Genomics to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Prostatype Genomics AB utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Prostatype Genomics's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Prostatype Genomics AB over time as well as its relative position and ranking within its peers.
Prostatype |
Prostatype Genomics Cash Per Share vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Prostatype Genomics's current stock value. Our valuation model uses many indicators to compare Prostatype Genomics value to that of its competitors to determine the firm's financial worth. Prostatype Genomics AB is rated top company in current valuation category among its peers. It also is considered to be number one stock in cash per share category among its peers . The ratio of Current Valuation to Cash Per Share for Prostatype Genomics AB is about 35,548,059 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Prostatype Genomics by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Prostatype Genomics' Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Prostatype Current Valuation vs. Competition
Prostatype Genomics AB is rated top company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Diagnostics & Research industry is at this time estimated at about 114.4 Million. Prostatype Genomics retains roughly 20.62 Million in current valuation claiming about 18% of equities under Diagnostics & Research industry.
Prostatype Cash Per Share vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Prostatype Genomics |
| = | 20.62 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Prostatype Genomics |
| = | 0.58 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Prostatype Cash Per Share Comparison
Prostatype Genomics is currently under evaluation in cash per share category among its peers.
Prostatype Genomics Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Prostatype Genomics, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Prostatype Genomics will eventually generate negative long term returns. The profitability progress is the general direction of Prostatype Genomics' change in net profit over the period of time. It can combine multiple indicators of Prostatype Genomics, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene tests. The company was founded in 2007 and is based in Solna, Sweden. Prostatype Genomics is traded on Stockholm Stock Exchange in Sweden.
Prostatype Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Prostatype Genomics. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Prostatype Genomics position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Prostatype Genomics' important profitability drivers and their relationship over time.
Use Prostatype Genomics in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Prostatype Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Prostatype Genomics will appreciate offsetting losses from the drop in the long position's value.Prostatype Genomics Pair Trading
Prostatype Genomics AB Pair Trading Analysis
The ability to find closely correlated positions to Prostatype Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Prostatype Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Prostatype Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Prostatype Genomics AB to buy it.
The correlation of Prostatype Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Prostatype Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Prostatype Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Prostatype Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Prostatype Genomics position
In addition to having Prostatype Genomics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sovereign ETFs Thematic Idea Now
Sovereign ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Sovereign ETFs theme has 17 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sovereign ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Prostatype Stock
To fully project Prostatype Genomics' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Prostatype Genomics at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Prostatype Genomics' income statement, its balance sheet, and the statement of cash flows.